Incidence of Statin Hepatotoxicity in Patients With Hepatitis C Shirin Khorashadi, Noelle K. Hasson, Ramsey C. Cheung  Clinical Gastroenterology and Hepatology  Volume 4, Issue 7, Pages 902-907 (July 2006) DOI: 10.1016/j.cgh.2006.03.014 Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 1 Percent change in liver enzyme levels from baseline to within 12 months after initiation of a statin therapy or diagnosis of hepatitis C in the no statin group. *P < .05 compared with the HCV-positive statin group. , HCV positive and no statin (n = 332); ■, HCV positive with statin (n = 166); □, HCV negative with statin (n = 332). Clinical Gastroenterology and Hepatology 2006 4, 902-907DOI: (10.1016/j.cgh.2006.03.014) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 2 Frequency and degree of hepatotoxicity within 12 months after initiation of a statin therapy or diagnosis of hepatitis C in the no statin group. Severity of increases in liver biochemistry values as defined in text. *P < .05 compared with the HCV-positive statin group. , HCV positive and no statin (n = 332); ■, HCV positive with statin (n = 166); □, HCV negative with statin (n = 332). Clinical Gastroenterology and Hepatology 2006 4, 902-907DOI: (10.1016/j.cgh.2006.03.014) Copyright © 2006 American Gastroenterological Association Terms and Conditions